Literature DB >> 17311764

In vivo noninvasive optical imaging of receptor-mediated RGD internalization using self-quenched Cy5-labeled RAFT-c(-RGDfK-)(4).

Zhao-Hui Jin1, Jesus Razkin, Veronique Josserand, Didier Boturyn, Alexeï Grichine, Isabelle Texier, Marie-Christine Favrot, Pascal Dumy, Jean-Luc Coll.   

Abstract

We reported that regioselectively addressable functionalized template (RAFT)-c(-RGDfK-)(4 )presenting four cyclic (Arg-Gly-Asp) (cRGD) peptides targets integrin alpha(V)beta(3) with an improved specificity compared with monomeric cRGD. In this study, we improved this vector by creating a "stealth" molecule in which a fluorescence quencher (Q) is linked to Cy5 via a disulfide bond (-SS-). RAFT-c(-RGDfK-)(4)-Cy5-SS-Q fluorescence is quenched unless activated by reduction during internalization. RAFT-c(-RGDfK-)(4)-Cy5-SS-Q fluorescence was negligible when compared with the control but totally recovered after cleavage of the disulfide bridge. Confocal microscopy showed that only the intracellular Cy5 signal could be detected using RAFT-c(-RGDfK-)(4)-Cy5-SS-Q, confirming that uncleaved extracellular molecules are not visible. Whole-body imaging of mice bearing subcutaneous tumors injected intravenously with RAFT-c(-RGDfK-)(4)-Cy5-SS-Q showed a very significant enhancement of the fluorescent contrast in tumors compared with the unquenched molecule. Histology of the tumor confirmed the intracellular accumulation of Cy5. These results demonstrate that the presence of a labile disulfide bridge between the targeting vector and a drug mimetic is an efficient way to deliver a dye, or a drug, intracellularly. In addition, this quenched RAFT-c(-RGDfK-)(4)-Cy5-SS-Q probe is a very powerful vector for imaging tumor masses and investigating in vivo RGD-mediated internalization.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17311764

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  13 in total

Review 1.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments.

Authors:  Y Waerzeggers; P Monfared; T Viel; A Faust; K Kopka; M Schäfers; B Tavitian; A Winkeler; A Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

2.  Application of click-click chemistry to the synthesis of new multivalent RGD conjugates.

Authors:  Mathieu Galibert; Lucie Sancey; Olivier Renaudet; Jean-Luc Coll; Pascal Dumy; Didier Boturyn
Journal:  Org Biomol Chem       Date:  2010-09-09       Impact factor: 3.876

3.  In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD.

Authors:  Lucie Sancey; Valérie Ardisson; Laurent M Riou; Mitra Ahmadi; Danièle Marti-Batlle; Didier Boturyn; Pascal Dumy; Daniel Fagret; Catherine Ghezzi; Jean-Philippe Vuillez
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-04       Impact factor: 9.236

4.  Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model.

Authors:  Anastassia Karageorgis; Michaël Claron; Romain Jugé; Caroline Aspord; Fabien Thoreau; Claire Leloup; Jérôme Kucharczak; Joël Plumas; Maxime Henry; Amandine Hurbin; Pascal Verdié; Jean Martinez; Gilles Subra; Pascal Dumy; Didier Boturyn; Abdel Aouacheria; Jean-Luc Coll
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

5.  Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers.

Authors:  Zhaofei Liu; Shuanglong Liu; Gang Niu; Fan Wang; Shuang Liu; Xiaoyuan Chen
Journal:  Mol Imaging       Date:  2010-02       Impact factor: 4.488

6.  Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma.

Authors:  Ruimin Huang; Jelena Vider; Joy L Kovar; D Michael Olive; Ingo K Mellinghoff; Philipp Mayer-Kuckuk; Moritz F Kircher; Ronald G Blasberg
Journal:  Clin Cancer Res       Date:  2012-08-22       Impact factor: 12.531

Review 7.  Progress in molecular imaging in endoscopy and endomicroscopy for cancer imaging.

Authors:  Supang Khondee; Thomas D Wang
Journal:  J Healthc Eng       Date:  2013       Impact factor: 2.682

8.  Optical tecnology developments in biomedicine: history, current and future.

Authors:  Shoko Nioka; Yu Chen
Journal:  Transl Med UniSa       Date:  2011-10-17

9.  Fluorescence imaging agents in cancerology.

Authors:  Aurélie Paganin-Gioanni; Elisabeth Bellard; Laurent Paquereau; Vincent Ecochard; Muriel Golzio; Justin Teissié
Journal:  Radiol Oncol       Date:  2010-09-09       Impact factor: 2.991

Review 10.  Optical image-guided surgery--where do we stand?

Authors:  Stijn Keereweer; Jeroen D F Kerrebijn; Pieter B A A van Driel; Bangwen Xie; Eric L Kaijzel; Thomas J A Snoeks; Ivo Que; Merlijn Hutteman; Joost R van der Vorst; J Sven D Mieog; Alexander L Vahrmeijer; Cornelis J H van de Velde; Robert J Baatenburg de Jong; Clemens W G M Löwik
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.